Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × selicrelumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Solid Tumors 2 Melanoma 2 Recurrence 1 Pancreatic Adenocarcinoma 1 Neoplasms 1 Lymphoma, B-Cell 1 Colorectal Neoplasms 1 Breast Neoplasms 1 Adenocarcinoma Pancreas 1

Interventions

Cyclophosphamide 138 Dexamethasone 119 Rituximab 76 fludarabine 66 Lenalidomide 64 Cytarabine 60 Gemcitabine 55 Bortezomib 53 fludarabine phosphate 52 venetoclax 47 pembrolizumab 46 Etoposide 46 Paclitaxel 45 Carboplatin 45 pomalidomide 44 Cisplatin 44 Peripheral Blood Stem Cell Transplantation 40 Radiotherapy 38 Filgrastim 38 Busulfan 33 Bevacizumab 33 Melphalan 32 carfilzomib 30 Calcium Dobesilate 30 Methotrexate 29 Cyclosporine 29 Azacitidine 28 Mycophenolic Acid 27 Nivolumab 26 Bendamustine Hydrochloride 26

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02225002 2018-08-28

Phase 1, Open-Label, Dose-Escalation Study of CP-870,893 in Patients With Solid Tumors

Abramson Cancer Center at Penn Medicine

Phase 1 Completed

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡